Actionable news
All posts from Actionable news

Jim Cramer on Valeant: This Is an Amazing Pharmaceutical Firm

NEW YORK (Real Money) -- Valeant (VRX) is amazing. It's just incredible. And it merits this move. First, there's regular Valeant, the company that's not yet combined with Salix (SLXP) , which it announced Sunday it is buying.

Valeant announced its quarter a day early and I am shocked at how much better it is doing than we thought. The Street was looking for organic growth -- the so-called same-store sales -- of 12% and it came in at 16%. The Street thought that it could have $2.2 billion in revenues and it came in at $2.3 billion. Cash flow? Thought to be $600 million; it comes in at $624 million.

The growth is led by the U.S., but it is broad everywhere.

Second, the company is an amazing acquirer. In their deck you can see some amazing numbers from its Bausch & Lomb acquisition in 2013. Its consumer business in the U.S. is up 13%. Its prescription business has zoomed 13% and it's going incredibly well with generics.

The top 20 global brands are doing amazingly well. They just get so much more out of their brands than other companies.

We know that one of the reasons why Allergan (AGN) fought them --...